Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.

Spenny ML, Walford J, Werchniak AE, Beltrani V, Brennick JB, Storm CA, Perry AE, Chapman MS.

Cutis. 2007 Feb;79(2):149-52.

PMID:
17388218
2.

Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream.

Chapman MS, Spencer SK, Brennick JB.

Arch Dermatol. 2003 Jul;139(7):943-4. No abstract available.

PMID:
12873902
3.

Topical imiquimod immunotherapy in the management of lentigo maligna.

Powell AM, Russell-Jones R, Barlow RJ.

Clin Exp Dermatol. 2004 Jan;29(1):15-21.

PMID:
14723712
4.

[Lentigo maligna treated with 5% imiquimod cream].

Martín T, Ojeda A, Martínez S, Vera A.

Actas Dermosifiliogr. 2005 Dec;96(10):700-2. Spanish.

PMID:
16476324
5.

[Imiquimod treatment of lentigo maligna to dermoscopic and histologic clearance].

Lorentzen HF, Weismann K.

Ugeskr Laeger. 2005 Sep 26;167(39):3696-7. Danish.

PMID:
16219219
6.

Treatment of lentigo maligna with imiquimod before staged excision.

Cotter MA, McKenna JK, Bowen GM.

Dermatol Surg. 2008 Feb;34(2):147-51. Epub 2007 Dec 17.

PMID:
18093206
7.

Topical imiquimod therapy for lentigo maligna.

Mahoney MH, Joseph MG, Temple C.

Ann Plast Surg. 2008 Oct;61(4):419-24. doi: 10.1097/SAP.0b013e31816714c8.

PMID:
18812714
8.

Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type.

Swetter SM, Chen FW, Kim DD, Egbert BM.

J Am Acad Dermatol. 2015 Jun;72(6):1047-53. doi: 10.1016/j.jaad.2015.02.008. Epub 2015 Mar 17.

PMID:
25791801
9.

Treatment of lentigo maligna with imiquimod 5% cream.

Hopson B, Richey D, Sajben FP.

J Drugs Dermatol. 2007 Oct;6(10):1037-40.

PMID:
17966182
10.

Extensive lentigo maligna clearing with topical imiquimod.

Epstein E.

Arch Dermatol. 2003 Jul;139(7):944-5. No abstract available.

PMID:
12873903
11.

Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.

Powell AM, Russell-Jones R.

J Am Acad Dermatol. 2004 May;50(5):792-6.

PMID:
15097969
12.

Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.

Michalopoulos P, Yawalkar N, Brönnimann M, Kappeler A, Braathen LR.

Br J Dermatol. 2004 Oct;151(4):903-6.

PMID:
15491436
13.

A pilot study of treatment of lentigo maligna with 5% imiquimod cream.

Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH.

Br J Dermatol. 2004 Aug;151(2):485-8.

PMID:
15327559
14.

A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions.

Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM.

Arch Dermatol. 2012 May;148(5):592-6. doi: 10.1001/archdermatol.2012.270.

PMID:
22431716
15.

Topical treatment of lentigo maligna melanoma with imiquimod 5% cream.

Borucki U, Metze D.

Dermatology. 2003;207(3):326-8. No abstract available.

PMID:
14571081
16.

In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod.

Alarcon I, Carrera C, Alos L, Palou J, Malvehy J, Puig S.

J Am Acad Dermatol. 2014 Jul;71(1):49-55. doi: 10.1016/j.jaad.2014.02.043. Epub 2014 Apr 13.

PMID:
24725478
17.

Treatment of lentigo maligna with imiquimod cream: a long-term follow-up study of 10 patients.

Van Meurs T, Van Doorn R, Kirtschig G.

Dermatol Surg. 2010 Jun;36(6):853-8. doi: 10.1111/j.1524-4725.2010.01560.x.

PMID:
20618370
18.
19.

Five-year recurrence rate of lentigo maligna after treatment with imiquimod.

Kai AC, Richards T, Coleman A, Mallipeddi R, Barlow R, Craythorne EE.

Br J Dermatol. 2016 Jan;174(1):165-8. doi: 10.1111/bjd.14311. Epub 2015 Dec 23.

PMID:
26595446
20.

Topical 5% imiquimod in the treatment of lentigo maligna.

Wong JG, Toole JW, Demers AA, Musto G, Wiseman MC.

J Cutan Med Surg. 2012 Jul-Aug;16(4):245-9.

PMID:
22784516

Supplemental Content

Support Center